BioCity’s first-in-class ADC targeting Glypican 3 clears FDA’s IND application

CAR-T Digest - August 2020

9 Apr 2024: BioCity’s first-in-class ADC targeting Glypican 3 clears FDA’s IND application

BioCity Biopharma gains FDA clearance for Phase 1 study of BC2027, a first-in-class ADC targeting Glypican 3 (GPC3)
BC2027 is BioCity’s second first-in-class ADC approved for clinical development, targeting Glypican 3 (GPC3) on cancer cell membranes
GPC3 is upregulated in certain cancers like HCC, lung, and esophageal, making it a rational treatment target as it is rarely expressed in normal liver tissues
BC2027 binds with high affinity to GPC3, internalizes into cancer cells, and releases its cancer-killing payload
In preclinical studies, BC2027 showed robust anticancer activity with over 90% tumor growth inhibition and was safe and tolerable